GlaxoSmithKline Plc (GSK)

37.70
0.39 1.05
NYSE : Health Technology
Prev Close 37.31
Open 37.25
Day Low/High 37.23 / 37.97
52 Wk Low/High 34.52 / 44.53
Volume 4.69M
Avg Volume 4.93M
Exchange NYSE
Shares Outstanding 2.48B
Market Cap 88.50B
EPS 0.80
P/E Ratio 21.44
Div & Yield 2.12 (5.59%)

Latest News

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, FLO, GNW, IART, LITE, MX, PDVW, PFPT, STO, TTWO Downgrades: AINV, BCO, BZH, CRCM, GSIT, GSK, IESC, ISRL, MLAB, MTCH, NEU, NNN, PZN, SGA Initiations: TRVG Read on to get TheStreet Quant Ratings' detailed report:

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Look How Overbought This Market Is

In my "what if" scenario for the Nasdaq, no matter what numbers I plugged in, the Momentum Indicator went down.

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta...

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar champion Danica Patrick talks about not being a gear head, her business ventures and how migraines have affected her life.

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol,...

When Will the Indexes Care?

Trying to find the answer to this often-asked question.

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European and U.S. stocks are expected to drift lower Thursday as the dollar continues to bear the brunt of global uncertainty on trade and tax policy.

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

The FDA cleared GSK's new drug for fast-track development with quicker regulatory review.

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA)...

Bad Day for Dollar and Healthcare

What stocks benefit from stronger dollar?

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSK, OPB, RES, SIX, TUP Downgrades: AXS, BPL, DXCM, KRA, OI, TRK, WMS Initiations: NTB Read on to get TheStreet Quant Ratings' detailed report:

5 Products You Didn't Know Were Made By Pfizer

5 Products You Didn't Know Were Made By Pfizer

Pfizer is reportedly planning to sell its consumer healthcare business in an auction next month

Warren Prods AIG Non-SIFI Label, GSK Joins List of Pfizer Consumer Beaus--ICYMI

Warren Prods AIG Non-SIFI Label, GSK Joins List of Pfizer Consumer Beaus--ICYMI

Here's what you need to know now for Wednesday, Oct. 25.

Pfizer to Sell Consumer Healthcare Business Next Month

Pfizer to Sell Consumer Healthcare Business Next Month

The business could go for more than $15 billion in an auction.

European Stocks Euphoria Is Running High ... Maybe Too High

European Stocks Euphoria Is Running High ... Maybe Too High

European stock markets are priced almost to perfection ahead of an earnings deluge.

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

Apple gains offset weakness in the healthcare sector. Small increases for benchmark indexes were enough to lead them to new closing records.

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Stocks are higher but retreat from intraday records on Monday.

Why Some Think It's 'Prime Time' for Amazon to Enter the Pharmacy Market

Why Some Think It's 'Prime Time' for Amazon to Enter the Pharmacy Market

The move is a natural for the e-commerce giant, and could wind up dramatically reducing the price of prescription drugs, according to Morgan Stanley.

This Year's Flu Season Could Be Devastating

This Year's Flu Season Could Be Devastating

Based on the flu season Australia just had, this flu season in the U.S. could be worse than usual.

These Stocks Pay You to Own Them

These Stocks Pay You to Own Them

Dividend paying stocks are often appealing to investors, especially ones from companies which consistently increased their dividends.

GSK And Innoviva Report Positive Headline Results From IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

GSK And Innoviva Report Positive Headline Results From IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single...

Trelegy Ellipta Approved As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The US

Trelegy Ellipta Approved As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The US

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone...

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

You would think that Nascar champion Danica Patrick would be a gear head who can talk makes, models and car parts and and car collector with garages brimming with rare autos. You would be wrong.

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion From The CHMP In Europe For Appropriate Patients With COPD

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion From The CHMP In Europe For Appropriate Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

TheStreet Quant Rating: C (Hold)